SCHEMBL25294152

SCHEMBL25294152

C=CC(=O)Nc1c(C)c(F)cc(F)c1C

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 9/20 0.46
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
GSTO1 P78417 1/20 0.38
F13A1 P00488 1/20 0.38
LMNA P02545 1/20 0.38
TGM1 P22735 1/20 0.38
TGM3 Q08188 1/20 0.38
BRD4 O60885 1/20 0.36
ALDH1A1 P00352 1/20 0.35
BTK Q06187 2/20 0.34
FGFR4 P22455 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29410354 0.81 TGM2 (0.46) TGM2MAOAMAOBGSTO1F13A1
SCHEMBL25247069 0.81 TGM2 (0.46) TGM2MAOAMAOBGSTO1F13A1
SCHEMBL25247241 0.80 TGM2 (0.41) TGM2MAOAMAOBF13A1LMNA
SCHEMBL30368203 0.80 TGM2 (0.41) TGM2MAOAMAOBF13A1LMNA
SCHEMBL30599488 0.78 TGM2 (0.40) TGM2GSTO1BTKFGFR4
SCHEMBL30599491 0.78 TGM2 (0.40) TGM2GSTO1BTKFGFR4
SCHEMBL25393645 0.78 TGM2 (0.40) TGM2GSTO1BTKFGFR4
SCHEMBL26026744 0.78 TGM2 (0.48) TGM2MAOAMAOBGSTO1F13A1
SCHEMBL30368171 0.77 TGM2 (0.46) TGM2HDAC1HDAC6BRD4ALDH1A1
SCHEMBL25287687 0.77 TGM2 (0.46) TGM2HDAC1HDAC6BRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630516-B2 Compounds NRG THERAPEUTICS LTD. (GB) 2026-05-19 US disclosed
EP-4208442-B1 MPTP INHIBITORS NRG THERAPEUTICS LTD (GB) 2025-10-22 EP disclosed
US-20250179028-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2025-06-05 US disclosed
EP-4486721-A1 ACRYLAMIDE COMPOUNDS NRG Therapeutics LTD (GB) 2025-01-08 EP disclosed
CN-118804911-A Acrylamide compound NRG治疗有限公司 2024-10-18 CN disclosed
US-20240067614-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD. (GB) 2024-02-29 US disclosed
US-20240067614-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD. (GB) 2024-02-29 US disclosed
US-20240067614-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD. (GB) 2024-02-29 US disclosed
WO-2023166303-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2023-09-07 WO disclosed
EP-4208442-A1 NOVEL COMPOUNDS NRG Therapeutics LTD (GB) 2023-07-12 EP disclosed
CN-116096705-A Novel compounds NRG治疗有限公司 2023-05-09 CN disclosed
WO-2022049376-A1 NOVEL COMPOUNDS NRG THERAPEUTICS LTD (GB) 2022-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630516-B2 Compounds CYP4B1, CYP1B1, NR4A1 TGM2 3518/4885MAOA 232/4885MAOB 290/4885
US-20240067614-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, CXCR2 TGM2 1850/4885MAOA 2502/4885MAOB 1456/4885
US-20250179028-A1 ACRYLAMIDE COMPOUNDS ACR, CCNI, FANCI TGM2 1716/4885MAOA 1433/4885MAOB 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.